Search

Displaying results 5291 - 5300 of 10000 in total
  1. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  2. Drug

    SB-509

    go.drugbank.com/drugs/DB05579
    Investigational

    SB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.

  3. Drug

    Ethyl macadamiate

    go.drugbank.com/drugs/DB11243
    Approved

    Ethyl macadamiate is derived from Macadamia terifolia seed oil. It is a non-volatile ester of ethyl alcohol and the fatty acids. … Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent.

  4. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).

  5. Drug

    Zeaxanthin

    go.drugbank.com/drugs/DB11176
    ApprovedInvestigational

    Zeaxanthin is a most common carotenoid alcohols found in nature that is involved in the xanthophyll cycle. … As a coexistent isomer of lutein, zeaxanthin is synthesized in plants and some micro-organisms.

  6. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

  7. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  8. Drug

    AT-7519

    go.drugbank.com/drugs/DB08142
    Investigational

    AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.

    Synonyms: 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  9. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

  10. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer. … The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system